Evelo Biosciences

63 articles with Evelo Biosciences

• 

  BioSpace Movers & Shakers, June 4

  6/4/2021

  Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.

• Evelo Biosciences Announces Appointment of Mark Plinio as Chief Commercial Officer

  6/1/2021

  Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of Mark Plinio as Chief Commercial Officer, effective June 14, 2021.

• Evelo Biosciences to Present at Upcoming Investor Conferences in June 2021

  5/26/2021

  Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that management will present at three upcoming virtual investor conferences in June:

• Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-inflammatory Product Candidate EDP2939 at the American Association of Immunologists Meeting

  5/13/2021

  On-track to initiate clinical development of EDP2939 in 2022

• Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights

  4/29/2021

  –Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting– –Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors– –Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets– –Multiple clinical data readouts expected over next 18 months– –Management to host conference call at 8:30

• Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021

  4/22/2021

  Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to report its first quarter 2021 financial results and discuss business highlights.

• Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis

  4/20/2021

  –Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting– –Meaningful improvements over placebo on clinical scores, including new data released on key IGA endpoints– –Initiation of Phase 2 trial of EDP1815 in atopic dermatitis expected in 3Q 2021–

• 

  BioSpace Movers & Shakers, April 16

  4/16/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of Directors

  4/15/2021

  Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointments of Luca Scavo as Chief Financial Officer (CFO), effective June 1, 2021, and Julie H. McHugh to its Board of Directors, effective immediately.

• Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference

  4/5/2021

  Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that management will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12th 2:15 p.m. ET.

• Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People

  3/23/2021

  Collaboration expected to accelerate access to Evelo’s lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in select developing markets and is Abdul Latif Jameel Health’s first biotechnology licensing agreement

• Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

  3/9/2021

  –Announced new positive data in human experimental model of inflammation of EDP1815– –Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021– –Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021– –Up to 8 clinical data readouts expected over next 18 months– –Management to host conference call at 8:30 a.m. ET–

• Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021

  3/2/2021

  Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, March 9, 2021 to report its fourth quarter and full year 2020 financial results and discuss business highlights.

• 

  BioSpace Movers & Shakers, Feb. 19

  2/19/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Evelo Biosciences Appoints John A. Hohneker, M.D. to Board of Directors

  2/16/2021

  Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of John Hohneker, M.D., to its Board of Directors.

• Evelo Biosciences Announces Pricing of Public Offering of Common Stock - Jan 29, 2021

  1/29/2021

  Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock, at a public offering price of $15.00 per share, before underwriting discounts and commissions.

• Evelo Biosciences Announces Proposed Public Offering of Common Stock - Jan 28, 2021

  1/28/2021

  Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that it intends to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering.

• 

  Clinical Catch-Up: January 18-22

  1/25/2021

  With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.

• Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis

  1/20/2021

  Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced new positive confirmatory data following completion of the mild and moderate atopic dermatitis cohort in its Phase 1b clinical trial.

• Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones

  1/7/2021

  Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates which act in the small intestine to drive systemic effects, today announced its strategic priorities and anticipated milestones for 2021.